10 completed, 3 recruiting, 2 terminated, 2 withdrawn. 7 Phase 4, 3 Phase 2, 2 Phase 1, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 2, Recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
| Early Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Central Nervous System Stimulants: new trials by email Literature Review of Central Nervous System Stimulants trials Research Report on Central Nervous System Stimulants
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants CNS Stimulant, Placebo, CNS Stimulant open label first phase - ADHD - Attention Deficit Disorder With Hyperactivity, Irritability | Phase 4 | Recruiting | Milton S. Hershey Medical Center | 136 | 2026-03-05 | 2026-04-20 |
| Measuring Acute Drug Demand in Humans II Blinded Study Medication - Condition 1, Blinded Study Medication - Condition 2, Blinded Study Medication - Condition 3 - Healthy Volunteers | Early Phase 1 | Withdrawn | Johns Hopkins University | 2025-11-15 | 2025-11-12 | |
| Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug Sleep Fragmentation, Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo), Sleep Continuity Disruption - Sleep Disorder, Healthy | Phase 2 | Completed | Johns Hopkins University | 148 | 2020-11-11 | 2025-09-24 |
| SUNOSI® (Solriamfetol) Pregnancy Registry Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants, No treatment - Narcolepsy, Obstructive Sleep Apnea | Recruiting | Axsome Therapeutics, Inc. | 1731 | 2019-07-31 | 2026-10-05 | |
| Stimulant Effects on Disruptive Behavior Stimulant - Attention Deficit Hyperactivity Disorder, Problem Behavior | Phase 4 | Recruiting | Matthew J O'Brien, PhD, BCBA-D | 10 | 2018-10-01 | 2025-03-17 |
| Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention CNS Stimulant - ADHD | Phase 4 | Terminated | Milton S. Hershey Medical Center | 11 | 2018-06-01 | 2025-08-26 |
| Adaptive Response to Intervention (RTI) for Students With ADHD Tier 1 Classroom Management, Daily Report Card (DRC), Enhanced DRC (DRC-E) - Attention Deficit Disorder With Hyperactivity | Phase 4 | Withdrawn | Florida International University | 2018-05-14 | 2025-08-07 | |
| Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis Blinded study medication - Knee Osteoarthritis | Phase 2 | Completed | Johns Hopkins University | 58 | 2017-11-01 | 2024-12-11 |
| Interactions Between Drug Effects and Environments II Paired, Stimulant or sedative, Placebo - Substance-Related Disorders | Phase 4 | Completed | University of Illinois at Chicago | 133 | 2015-11-01 | 2021-05-19 |
| Omega-3 Supplementation to ADHD Medication in Children Omega-3 Fatty Acid, ADHD Medication - Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation | Phase 4 | Completed | Massachusetts General Hospital | 21 | 2014-07-01 | 2017-06-29 |
| Effects of Hallucinogens and Other Drugs on Mood and Performance Hallucinogens and psychoactive substances - Healthy | Phase 1 | Completed | Johns Hopkins University | 20 | 2014-04-01 | 2019-05-16 |
| Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth behavior therapy, Extended release (ER) methylphenidate product, monitoring - ADHD, Growth | Phase 3 | Completed | Florida International University | 230 | 2010-11-01 | 2017-07-14 |
| Multidimensional Measurement of Psychopharmacological Treatment Response Pharmacological Intervention - Autism Spectrum Disorders, Mood Disorders | Completed | Child Psychopharmacology Institute | 44 | 2010-08-01 | 2014-01-06 | |
| Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD Stimulants plus Lovaza, Stimulants plus placebo - Attention Deficit Hyperactivity Disorder | Phase 4 | Terminated | Antonios Likourezos | 15 | 2009-12-01 | 2023-12-14 |
| Safety Study of Atomoxetine and Cerebrovascular Outcomes atomoxetine, Stimulants, No intervention (general population) - Cerebrovascular Accident, Transient Ischemic Attack | Completed | Eli Lilly and Company | 72000 | 2008-01-01 | 2009-09-15 | |
| Treatment Compliance in Children and Adolescents on ADHD Medication Atomoxetine, stimulants (any approved ADHD medication) - ADHD | Completed | Eli Lilly and Company | 518 | 2007-11-01 | 2009-08-27 | |
| The Discriminative Effects of Tramadol in Humans tramadol, placebo, Hydromorphone - Opioid Abuse, Opioid Addiction | Phase 1 / Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 20 | 2007-11-01 | 2017-10-17 |
Attention Deficit Disorder with Hyperactivity (10) · Sleep Wake Disorders (2) · Aggression (1) · Agnosia (1) · Autism Spectrum Disorder (1) · Ischemic Attack, Transient (1) · Mood Disorders (1) · Narcolepsy (1) · Opioid-Related Disorders (1) · Osteoarthritis, Knee (1) · Pain (1) · Parasomnias (1) · Problem Behavior (1) · Sleep Apnea Syndromes (1) · Sleep Apnea, Obstructive (1)
Johns Hopkins University (4) · Eli Lilly and Company (2) · Florida International University (2) · Milton S. Hershey Medical Center (2) · Antonios Likourezos (1) · Axsome Therapeutics, Inc. (1) · Child Psychopharmacology Institute (1) · Massachusetts General Hospital (1) · Matthew J O'Brien, PhD, BCBA-D (1) · National Institute on Drug Abuse (NIDA) (1) · University of Illinois at Chicago (1)
United States (16) · Germany (1)
Alexandra Kearson, BA (1) · Bill J Duke, M.A., Ph.D. (1) · Claudia Campbell, PhD (1) · Claudia M Campbell, Ph.D. (1) · Emma Childs, PhD (1) · Eric C Strain, M.D. (1) · Eric C Strain, MD (1) · Hiroto Kuwabara, MD (1) · James G Waxmonsky, MD (1) · Jeannie Leoutsakos, PhD (1) · Juan D Pedraza, MD (1) · Justin Stricklahd, PhD (1) · Kathleen Malloy, MD (1)
PMID 21467190, PMID 24705867, PMID 31473291, PMID 34366928, PMID 34571023, PMID 37058600, PMID 38152462, PMID 41481837
R01DA018125 (1), R01DA042751 (1), R21DA033488 (1), U01HL150568 (1)